CureVac (NASDAQ: CVAC) furnishes Q3 and nine-month 2025 results

Rhea-AI Filing Summary

CureVac N.V. submitted a Form 6-K reporting that it issued a press release with its financial results for the third quarter and first nine months of 2025, along with a business update. The furnished information, excluding the CEO’s statement, is incorporated by reference into BioNTech SE’s Form F-4 registration statement.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-39446

CureVac N.V.

(Exact Name of Registrant as Specified in Its Charter)

Friedrich-Miescher-Strasse 15, 72076

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x          Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes ¨          No x

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes ¨           No x

On November 24, 2025, CureVac N.V. (the “Company”) issued a press release announcing the Company’s financial results for the third quarter and first nine months of 2025 and provided a business update.

The information included in this Form 6-K (including Exhibit 99.1, but excluding the statement of the Company’s Chief Executive Officer contained in Exhibit 99.1 hereto) shall be deemed to be filed and incorporated by reference in BioNTech SE’s registration statement on Form F-4 (File No. 333-289468) and to be part thereof from the date on which this Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CureVac N.V.
	(Registrant)
By:	/s/ Axel Sven Malkomes		By:	/s/ Alexander Zehnder
	Chief Financial Officer			Chief Executive Officer
	Date: November 24, 2025

EXHIBIT INDEX

EXHIBIT NO.		DESCRIPTION
99.1		CureVac N.V. Press Release dated November 24, 2025

FAQ

What did CureVac (CVAC) disclose in this November 2025 Form 6-K?

CureVac filed a Form 6-K stating it issued a press release with financial results for the third quarter and first nine months of 2025 and a business update. The filing primarily serves to furnish that information to investors and regulators.

Which reporting period does CureVac’s Form 6-K in November 2025 cover?

The Form 6-K relates to CureVac’s financial results for the third quarter and the first nine months of 2025. These results, together with a broader business update, are contained in the referenced press release attached as Exhibit 99.1 to the submission.

How is CureVac’s November 2025 Form 6-K linked to BioNTech SE’s Form F-4?

CureVac’s Form 6-K states that the included information, except the CEO’s statement, is deemed filed and incorporated by reference into BioNTech SE’s Form F-4 registration statement, becoming part of that document unless later filings supersede it.

What is included as Exhibit 99.1 to CureVac’s November 2025 Form 6-K?

Exhibit 99.1 is a CureVac press release dated November 24, 2025. It contains the company’s financial results for the third quarter and first nine months of 2025, as well as a business update summarizing operational and strategic developments.

Which SEC annual report form does CureVac (CVAC) use as a foreign issuer?

CureVac indicates that it files its annual reports on Form 20-F, the standard SEC annual report format for foreign private issuers. This selection reflects its status as a foreign company reporting under U.S. securities regulations.

Who signed CureVac’s November 2025 Form 6-K submission?

The Form 6-K was signed on behalf of CureVac by Chief Financial Officer Axel Sven Malkomes and Chief Executive Officer Alexander Zehnder. Their signatures confirm authorization and responsibility for the information furnished in the submission.